Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osoresnontrine - Boehringer Ingelheim

Next Previous
Drug Profile

Osoresnontrine - Boehringer Ingelheim

Alternative Names: BI-409306; SUB 166499

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Antidementias; Antipsychotics; Nootropics; Pyrans; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Psychotic disorders; Schizophrenia
  • No development reported Cognition disorders

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in USA (PO, Tablet)
  • 12 Aug 2022 Boehringer Ingelheim completes a phase I trial in Cognition disorders (In volunteers) in USA (PO, Tablet) (NCT04602221)
  • 30 Sep 2021 Boehringer Ingelheim terminates a phase II trial for Schizophrenia (Adjunctive treatment) in USA, Canada, France, Japan, Spain, South Korea and Taiwan, due to COVID-2019 infections (PO) (NCT03351244) (EudraCT2017-002369-23)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top